ulcerative colitis. Ulcerative colitis, unspecified
Conditions
Interventions
Intervention 1: Two capsules (each capsule contains 250 mg Achillea wilhelmsii) daily for a month, from Kermnanshah apothecary. Intervention 2: Two capsules (each capsule contains 250 mg hydroxypropyl
Treatment - Drugs
Placebo
Two capsules (each capsule contains 250 mg Achillea wilhelmsii) daily for a month, from Kermnanshah apothecary
Two capsules (each capsule contains 250 mg hydroxypropyl methylcellulose from Sigma company) daily for a month
Sponsors
Vice Chancellor for Research, Kermanshah University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria:age>18- ability to swallow the capsule- patients who sign the testimonials and cooperate during the study.(In cases which patients do not have education,the investigator should read the testimonial for them.if they are satisfied, the investigator can include them to the study.)- patients who are not cured with Achillea wilhelmsii during a last month.-Patients who their diseases are approved by complete medical evaluation, colonoscopy, pathology and laboratory data.-Only patients with mild to moderate ulcerative colitis can be include to this study. Exclusion criteria:smokers-pregnant patients and nursing mothers-patients who have to use other drugs that interference with this medication (such as systemic NSAID, antihistamins or systemic antibiotics during last 2 weeks)- patients who are suffering from other diseases in addition to ulcerative colitis that the etiology of them are oxidative stress, such as metabolic syndrome, diabetic leg ulcer, coronary arterial disease, pulmonary infection, patients who are disposed to a serious health danger, such as severe cardiac, liver or renal diseases.- If significant side effects occur, the patient will be excluded from the study and followed to end of the study.- If a patient do not want to continue to cooperating for any reasons, he will be excluded from the study.- patients with severe allergy to this plant (dermatitis contact) will be excluded.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of excretion daily. Timepoint: before using the drug-2 weeks after using the drug-30 days after using the drugs. Method of measurement: based on Mayo clinic questionary and ESR,CBC,CRP.;Rate of rectal bleeding. Timepoint: before using the drug-2 weeks after using the drug-30 days after using the drugs. Method of measurement: based on Mayo clinic score, CRP, CBC, and ESR. | — |
Secondary
| Measure | Time frame |
|---|---|
| Photo sensitivity- gastrointestinal disorders. Timepoint: Two weeks after using the drug- 30 days after using the drug. Method of measurement: based on side effect questionary. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahtab Amiri
Faculty of pharmacy, Kermanshah University of Medical Sciences
Outcome results
None listed